Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa

Background

The Omicron SARS-CoV-2 variant of concern (VOC) has been dominant globally since November 2021, with several lineages causing surges in infections (Iketani et al., 2022, Tegally et al., 2022, Viana et al., 2022). South Africa experienced an initial large BA.1 infection surge from November 2021 to January 2022. BA.1 was then replaced by BA.2 but with no increase in cases numbers, and this was followed by a BA.4/BA.5 infection surge between April and June 2022 (Tegally et al., 2022, Viana et al., 2022). The combination of mutations in BA.4/BA.5 appear to confer a growth advantage over BA.2, as well as immune escape from vaccine-derived and BA.1 elicited antibodies (Khan et al., 2022, Tegally et al., 2022). A growing number of BA.4 and BA.5 infections are now being reported globally (Callaway, 2022, UK Health Secuurity Agency, 2022).

We therefore compared outcomes of laboratory-confirmed SARS-CoV-2 infections during the recent resurgence (proxy for BA.4/ BA.5 infection) with outcomes during each of the four previous waves in South Africa, each of which were caused by a different variant or lineage, using data on patients with laboratory-confirmed SARS-CoV-2 infection aged ≥20 years using public sector services in the Western Cape Province, South Africa.

Methods

We conducted a cohort study using de-identified data from the Western Cape Provincial Health Data Centre (WCPHDC) of public sector patients aged ≥20 years with a laboratory confirmed COVID-19 diagnosis (positive SARS-CoV-2 PCR or antigen test). The Western Cape has nearly 7 million inhabitants, of whom approximately 75% use public sector health services (Western Cape Department of Health, 2020). The WCPHDC and methods for this study have previously been described in detail (Boulle et al., 2019, Davies et al., 2022, Hussey et al., 2022, Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, 2020). Briefly, for this analysis, waves of infection were defined as starting and ending when the 7-day moving average of public sector COVID-19 hospital admissions exceeded and dropped below 5 and 12 per million population respectively. We included cases diagnosed from seven days before the wave start to seven days before the wave end date to account for the lag between infection/first symptoms and hospitalization. We thus included data on cases diagnosed from 1-21 May 2022 for the BA.4/BA.5 wave, with follow-up through to 11 June 2022, corresponding to the period when BA.4/BA.5 dominated in the province (Network for Genomic Surveillance in South Africa, 2022).

We used Cox regression adjusted for age, sex, geographic location, comorbidities, service pressure (number of weekly admissions in the health district) at time of diagnosis, prior diagnosed infection (≥1 laboratory confirmed SARS-CoV-2 diagnosis ≥90 days previously) and SARS-CoV-2 vaccination to assess differences in the following COVID-19 outcomes between waves driven by different variants: (i) death and (ii) death or severe hospitalization (admission to intensive care or mechanical ventilation or oral/intravenous steroid prescription). We only included outcomes within 21 days of COVID-19 diagnosis for comparable ascertainment across all waves. All deaths within 21 days of a COVID-19 diagnosis were included unless a clear non-COVID-19 cause of death was recorded. For patients with recorded South African national identity numbers, data are linked to the South African vital registry to identify deaths not recorded in the WCPHDC. Vaccination data was obtained by linking the South African national identifier to the Electronic Vaccine Data System which records all vaccines administered in the country. The only vaccines available in South Africa to date are BNT162b and Ad26.COV2.S. Vaccination status was categorized as either (i) “boosted” (three or more homologous or heterologous doses of any vaccine), (ii) “two doses” (two doses of any vaccine) or (iii) “single dose” (single dose of Ad26.COV2.S), as the latter is considered complete primary vaccination in South Africa.

The study was approved by the University of Cape Town and Stellenbosch University Health Research Ethics Committees and Western Cape Government: Health. Individual informed consent requirement was waived for this secondary analysis of de-identified data.

Results

We included 3,793 patients diagnosed in the BA.4/BA.5 wave and 27,614 (BA.1), 68,715 (Delta), 54,268 (Beta) and 40,204 (ancestral) in waves driven by previous variants (Table 1). The proportion with prior diagnosed infection was substantially higher in the BA.4/BA.5 (18.9%) and BA.1 (11.9%) waves compared to previous waves (<3%). In the BA.4/BA.5 wave, 12.6% of COVID-19 cases had received “single dose” vaccination, 35.3% had received “two doses” and 6,7% were “boosted” vaccinees.

The adjusted hazard of severe hospitalization or death in the BA.4/BA.5 wave was similar to the BA.1 wave (adjusted hazard ratio [aHR] 1.01; 95% Confidence Interval: 0.92; 1.12) (Table 2). Both Omicron-driven waves had lower hazards of severe hospitalization or death than previous waves (Table 2). Prior diagnosed infection was strongly protective against severe hospitalization or death (aHR 0.19; 95% CI 0.16; 0.22) as was vaccination with aHR (95% CI) of 0.24 (0.15; 0.39); 0.58 (0.54; 0.63) and 0.55 (0.49; 0.62) for “boosted”, “two doses” and “single dose”, respectively. In a model not adjusting for vaccination and prior diagnosed infection, the hazard of severe hospitalization or death was reduced in the BA.4/BA.5 vs. BA.1 waves (aHR 0.80; 95%CI: 0.72;0.88). In an analysis restricted to the BA.4/BA.5 period, prior diagnosed infection remained strongly protective against severe hospitalization or death (aHR 0.16; 95% CI 0.09; 0.27) as did vaccination (aHR [95% CI]: 0.27 (0.16; 0.43); 0.46 (0.37; 0.57) and 0.50 (0.34; 0.73) for “boosted”, “two doses” and “single dose”, respectively. Results were all similar when examining the outcome of death alone.

Discussion

Using the period of diagnosis as a proxy for being infected with different Omicron lineages in the Western Cape, we found no difference in the risk of severe COVID-19 hospitalization or death during the BA.4/BA.5 period compared to the BA.1 period, both of which had better outcomes than previous waves. Strong protection against severe COVID-19 conferred by prior infection and vaccination was retained in the BA.4/5 wave, with three homologous doses of Ad26.COV2.S or BNT162b2 or a heterologous combination of these providing 73% protection (95% CI 57; 84%) against severe COVID-19 hospitalization or death amongst laboratory-confirmed cases.

A study in animals recently suggested that BA.4/BA.5 may be more pathogenic than BA.2 (Kimura et al., 2022). Although we did not compare BA.4/BA.5 with BA.2 directly as BA.2 did not cause a distinguishable surge in infections in the Western Cape, disease severity of BA.2 and BA.1 are similar (Lewnard et al., 2022) and we found no evidence of worse clinical outcomes with BA.4/BA.5 compared to BA.1. Nonetheless, our findings need to be interpreted in the context of South African SARS-CoV-2 epidemiology with progressively increasing seroprevalence due to prior infection (mostly undiagnosed) and/or vaccination (Bingham et al., 2022, Madhi et al., 2022, Sun et al., 2022). For example, among blood donors, after the BA.1 wave the estimated national prevalence of anti-nucleocapsid antibodies was 87% (indicating previous infection) with a further 10% having anti-spike antibodies only (suggesting vaccination without prior infection) (Bingham et al., 2022). Indeed, our finding of less severe outcomes during BA.4/BA.5 vs. BA.1 in models not accounting for vaccination and prior diagnosed infection, suggests that the observed continued ecologic decoupling of COVID-19 cases and severe outcomes is at least partly due to growing protection against severe disease from both prior infection and vaccination. With the progression of the SARS-CoV-2 pandemic globally, it is increasingly difficult to determine the clinical severity of any variant in a completely naïve individual. However, for health service planning this is less relevant than the real-world effect in populations with varying degrees of immune protection (Mefsin et al., 2022). For example, although we showed similar risk of severe hospitalization or death in the BA.4/BA.5 and BA.1 waves when adjusted for vaccination and prior diagnosed infection, the actual burden of admissions and deaths was much lower in the BA.4/BA.5 waves, with the peak 7-day moving average of admissions and deaths being 222 and 36 in the BA.1 wave vs. 66 and 9 in the BA.4/BA.5 wave. The ability to use routine data to rapidly assess the relative severity of waves caused by different lineages and variants adjusted for comorbidities, vaccination and prior infection has been especially valuable for local health service planning (Davies et al., 2022).

To our knowledge, this is one of the first comparisons of clinical severity of BA.4/BA.5 infections with previous variants with relatively complete adjustment for comorbidities and vaccination among all diagnosed cases. Nonetheless, this type of data and analysis have several limitations which have been described in detail previously (Davies et al., 2022). These include using the time of infection as a proxy for the variant causing infection rather than actual genomic sequencing or PCR test proxies (Wolter et al., 2022) which would be more accurate and overcome challenges with comparing disease severity across waves due to differences in testing practices, treatment availability and health service pressures. Notably, testing in the BA.4/BA.5 wave was at the lowest levels since the start of the pandemic with less testing of patients with milder disease, hence we may have over-estimated disease severity in this wave. With routine data we were unable to distinguish between severe hospitalizations and deaths where the diagnosis of COVID-19 may have been incidental or contributory rather than causal, and had incomplete ascertainment of key covariates especially prior diagnosed infection due to substantial missed diagnoses, vaccinations received outside of the province or without submitting a South African identity number and undiagnosed comorbidities as we can only adjust for those algorithmically identified in the WCPHDC.

In conclusion, we found similar disease severity amongst diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 with strong protection against severe outcomes conferred by prior infection and vaccination, especially if boosted. Ensuring that individuals at high risk of severe COVID-19 outcomes have at least three vaccine doses remains a key strategy for limiting the public health impact of further COVID-19 waves.

Funding Sources

We acknowledge funding for the Western Cape Provincial Health Data Centre from the Western Cape Department of Health, the US National Institutes for Health (R01 HD080465, U01 AI069924), the Bill and Melinda Gates Foundation (1164272, 1191327), the United States Agency for International Development (72067418CA00023), the European Union (101045989) and the Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill & Melinda Gates and Minderoo Foundations (INV-017293). Funding was also received from Wellcome (203135/Z/16/Z [RJW, GM, WCPHDC], 222574 [RJW, WCPHDC] 214321/Z/18/Z [GM]) and the Medical Research Council of South Africa (RJW, MAD). RJW additionally receives support from the Francis Crick Institute which is funded by Wellcome (FC0010218), MRC (UK) (FC0010218), and Cancer Research UK (FC0010218). GM is also funded by the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (Grant No 64787). The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The opinions, findings and conclusions expressed in this manuscript reflect those of the authors alone. For the purposes of open access the author has applied a CC-BY public copyright to any author accepted version arising from this submission.

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical approval statement

The study was approved by the University of Cape Town and Stellenbosch University Health Research Ethics Committees and Western Cape Government: Health. Individual informed consent requirement was waived for this secondary analysis of de-identified data.